Table 1.
Patient and tumor characteristics
| Discovery cohort (atezolizumab cohort) | Validation cohort (nivolumab cohort) | |
|---|---|---|
| Characteristic | N (%) | N (%) |
| No. of patients | ||
| 81 | 139 | |
| Age, years | ||
| Median (range) | 70 (36–84) | 69 (43–83) |
| Sex | ||
| Male | 64 (79.0) | 112 (80.6) |
| Female | 17 (21.0) | 27 (19.4) |
| ECOG performance status | ||
| 0 | 48 (59.3) | 71 (51.1) |
| 1 | 24 (29.6) | 62 (44.6) |
| 2 | 9 (11.1) | 6 (4.3) |
| Smoking status | ||
| Never | 16 (19.8) | 20 (14.4) |
| Current or former | 65 (80.2) | 119 (85.6) |
| Histology | ||
| Adenocarcinoma | 55 (67.9) | 76 (54.7) |
| Squamous cell carcinoma | 20 (24.7) | 55 (39.6) |
| Other | 6 (7.4) | 8 (5.8) |
| Stage at treatment | ||
| III | 13 (16.0) | 28 (20.1) |
| IV | 61 (75.3) | 101 (72.7) |
| Recurrence | 7 (8.6) | 10 (7.2) |
| No. of previous systemic therapies* | ||
| Median (range) | 2 (1–7) | 1 (1–8) |
| Previous treatment with PD-1/PD-L1 inhibitors | ||
| Nivolumab | 5 (6.2) | 0 |
| Pembrorizumab | 4 (4.9) | 0 |
| Duruvaumab | 1 (1.2) | 0 |
| None | 71 (87.7) | 139 (100) |
| EGFR mutation | ||
| Presence | 15 (18.5) | 11 (7.9) |
| Absence | 53 (65.4) | 97 (69.8) |
| Unknown | 13 (16.0) | 31 (22.3) |
| ALK rearrangement | ||
| Presence | 0 | 1 (0.7) |
| Absence | 57 (70.4) | 100 (71.9) |
| Unknown | 24 (29.6) | 38 (27.3) |
*Includes (neo)adjuvant therapy
ALK, anaplastic lymphoma kinase, ECOG Eastern Cooperative Oncology Group, EGFR epidermal growth factor receptor, PD-1 programmed cell death protein 1, PD-L1 programmed death-ligand 1